| |
Univariate analysis
|
P value
|
Multivariate analysis
|
P value
|
|---|
|
HR (95% CI)
|
HR (95% CI)
|
|---|
|
Age at diagnosis
|
1.03 (1.01–1.05)
|
< 0.001
|
1.02 (1.00–1.03)
|
0.072
|
|
Gender
|
|
Female
|
1.00
|
0.517
| | |
|
Male
|
0.89 (0.63–1.26)
|
|
Tumor stage
|
|
Locally advanced tumor
|
1.00
|
0.008
|
1.00
|
0.001
|
|
Metastatic disease
|
0.56 (0.37–0.86)
|
0.47 (0.30–0.72)
|
|
Tumor location
|
|
Head
|
1.00
|
0.202
| | |
|
Body/tail
|
1.25 (0.89–1.76)
|
|
Tumor size (cm)
|
0.97 (0.84–1.13)
|
0.733
| | |
|
CA 19–9 levels at diagnosis
|
|
< 1000 U/mL
|
1
|
0.143
| | |
|
> 1000 U/mL
|
0.76 (0.53–1.10)
|
|
Weight loss at diagnosis
|
|
< 10% BW
|
1
|
0.420
| | |
|
> 10% BW
|
0.87 (0.62–1.22)
|
|
Chemotherapy
|
4.68 (3.18–6.89)
|
< 0.001
|
3.69 (2.33–5.85)
|
< 0.001
|
|
PERT
|
1.80 (1.24–2.62)
|
0.002
|
1.81 (1.23–2.66)
|
0.002
|
- BW body weight, CI confidence interval, HR hazard ratio, PERT pancreatic enzyme replacement therapy
